A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.

已完结 10 由 77 发布于 2025/2/6 16:07:35

DOI:10.1007/s12185-022-03494-7
作者：Koji Kato, Nobuharu Fujii, Shinichi Makita, Hideki Goto, Junya Kanda, Kazuyuki Shimada, Koichi Akashi, Koji Izutsu, Takanori Teshima, Natsuko Fukuda, 
文献类型：期刊论文
补充材料：只需要正文

Springer

Abstract：Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-targeting chimeric antigen receptor T‑cell therapy. We recently reported the 3-month follow-up results of a phase 2, multicenter, ope

应助信息

8小时前

li75

6fcb037ee46111efa7bb34735aa3bc31.pdf 已采纳

8小时前

Book学术机器人

2025/2/6 16:07:35 未找到该文献，机器人已退出，请等待人工下载

2025/2/6 16:07:35 Book学术AI机器人收到请求，开始寻找文献

2025/2/6 16:07:35 已向机器人发送请求

8小时前

77 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网磷肥种类对石灰性土壤马铃薯产量和磷肥利用率的影响